Gabriella Giancane1,2, Nicolino Ruperto1. 1. IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia - PRINTO. 2. Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy.
Abstract
PURPOSE OF REVIEW: The present review highlights the advances in disease outcome achieved with currently available biologic medications and future perspectives for JIA management. RECENT FINDINGS: In the last two decades, the management of juvenile idiopathic arthritis (JIA) has been revolutionized by appropriate legislative initiatives, the existence of very large collaborative networks and the increased availability of the novel biologic medications. SUMMARY: A more rational approach to the management of JIA is being fostered by the recent publication of therapeutic recommendations, consensus treatment plans and for a treat-to-target strategy.
PURPOSE OF REVIEW: The present review highlights the advances in disease outcome achieved with currently available biologic medications and future perspectives for JIA management. RECENT FINDINGS: In the last two decades, the management of juvenile idiopathic arthritis (JIA) has been revolutionized by appropriate legislative initiatives, the existence of very large collaborative networks and the increased availability of the novel biologic medications. SUMMARY: A more rational approach to the management of JIA is being fostered by the recent publication of therapeutic recommendations, consensus treatment plans and for a treat-to-target strategy.
Authors: Alberto Martini; Daniel J Lovell; Salvatore Albani; Hermine I Brunner; Kimme L Hyrich; Susan D Thompson; Nicolino Ruperto Journal: Nat Rev Dis Primers Date: 2022-01-27 Impact factor: 65.038